Eledon Pharmaceuticals (ELDN) - News Mentions

Sign up to add (ELDN) to your portfolio and access more historical data.

00%
Est. daily news mentions.

Sign up to access historical data

Sign up

Similar companies

Company News Mentions
Amgen
Amgen
AMGN		 0 100%
Gilead Sciences
Gilead Sciences
GILD		 1 0%
Catalyst Pharmaceuticals
Catalyst Pharmaceuticals
CPRX		 0 100%
Inovio Pharmaceuticals
Inovio Pharmaceuticals
INO		 1 0%
Anavex Life Sciences
Anavex Life Sciences
AVXL		 0 0%
Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2025 Outlook
January 12
Eledon Pharmaceuticals (NASDAQ:ELDN) Stock Price Down 3.9% – What’s Next?
January 7
HC Wainwright Reiterates Buy Rating for Eledon Pharmaceuticals (NASDAQ:ELDN)
November 22
ELDN FY2024 EPS Forecast Raised by Cantor Fitzgerald
November 18
What is Lifesci Capital’s Forecast for ELDN FY2024 Earnings?
November 16
Eledon Pharmaceuticals, Inc.'s (NASDAQ:ELDN) market cap dropped US$48m last week; individual investors who hold 57% were hit as were institutions
November 13
Eledon Pharmaceuticals Announces Recent Business Highlights and Third Quarter 2024 Financial Results
November 12
Eledon Pharmaceuticals : Announces Recent Business Highlights and Third Quarter 2024 Financial Results Form 8 K
November 12
Eledon Pharmaceuticals to Participate in Guggenheim Securities Inaugural Healthcare Innovation Conference
November 6
Biotechnology Value Fund L P's Strategic Acquisition in Eledon Pharmaceuticals
October 30
Noble Financial Reaffirms Their Buy Rating on Eledon Pharmaceuticals (ELDN)
October 29
Promising Clinical Trials and Strong Financial Position Make Eledon Pharmaceuticals a Compelling Investment
October 29
Eledon Pharmaceuticals : Announces Pricing of $85 Million Underwritten Offering of Common Stock and Pre Funded Warrants Form 8 K
October 29
Eledon Pharmaceuticals Announces $85 Million Stock Offering
October 29
Eledon Pharmaceuticals Announces Pricing of $85 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
October 28
Eledon Pharmaceuticals Announces Positive Initial Data from Subjects with Type 1 Diabetes Treated with Tegoprubart as Part of an Immunosuppression Regimen Following Islet Transplantation in Investigator-Initiated Trial at UChicago Medicine
October 28

Month over Month

Est. daily news mentions.

Dec 2024 0
Nov 2024 0
Oct 2024 0
Sep 2024 0
Aug 2024 0

How often is Eledon Pharmaceuticals mentioned in the news?

Eledon Pharmaceuticals was mentioned an estimated 0 times in online prominent news articles yesterday.

Analyzing News Mentions, how is Eledon Pharmaceuticals performing compared to its industry peers?

Eledon Pharmaceuticals underperforms its industry peers when it comes to News Mentions, ranking dead last.

Has there been an increase or decrease in news mentions of Eledon Pharmaceuticals in the last month?

There has been no significant change in the number of news mentions for Eledon Pharmaceuticals' compared to the last month.

Why is it important to track news mentions for Eledon Pharmaceuticals?

By monitoring mentions in the news for Eledon Pharmaceuticals, investors stay up to date on impactful events for the company, its industry and its competitors. Positive news might affect price in a positive way and negative news might affect price in a negative way. By tracking mentions over time, investors can also identify patterns, explore popularity and make informed decisions based on the evolving perception of Eledon Pharmaceuticals, ultimately improving their investment strategies.

Sign up and get more insights on Eledon Pharmaceuticals.

The analytics provided are estimates and not a substitute for professional advice. All investments involve risks, including possible capital loss.
About Us

AltIndex revolutionizes investing with advanced alternative data analytics, smart insights, and stock alerts, presented in an easy-to-use dashboard powered by comprehensive company data from across the internet.



App download

Legal Disclaimer
The information provided by AltIndex is solely for informational purposes and not a substitute for professional financial advice. Investing in financial markets carries inherent risks, and past performance doesn't guarantee future results. It's crucial to do your research, consult with financial experts, and align your financial objectives and risk tolerance before investing. AltIndex creators and operators are not liable for any financial losses incurred from using this information. Users should exercise caution, seek professional advice, and be prepared for the risks involved in trading and investing in financial assets, only investing what they can afford to lose. The information in this application, derived from publicly available data, is believed to be reliable but may not always be accurate or current. Users should verify information independently and not solely rely on this application for financial decisions. By using AltIndex, you acknowledge that it doesn't offer financial advice and agree to consult a qualified financial advisor before making investment decisions.

© 2025 AltIndex. All rights reserved.

Top Stocks

Trending Stocks
Trending Stocks on WallStreetBets
Trending Stocks on Reddit
Top Stocks
Top Stock Performers Today
Bottom Stock Performers Today
Best Airlines Stocks
Best Bank Stocks
Best Semiconductor Stocks
Best Energy Stocks
Best Fintech Stocks
Best Robotics Stocks
Best Insurance Stocks

Our Data

Datasets
Stock alerts
AI Stock Picks
AI Stock Picks - Results
Fear & Greed Index
Meme Stocks
Threads Users
Stock Predictor
Stock Picking Reviews
Stock Trading Signals
House & Congress Trading
Earnings Calendar
Index

AltIndex

News
Pricing
Sign up
Log in
API
Journalist Access
Data Disclaimer
Contact